Join us for this Science Talk with Drs. Ali Salanti, Max M Søgaard, and Louise Leth Hefting on development of a virus-like particle (VLP)-based COVID-19 vaccine and what the companies behind it, AdaptVac and ExpreS2ion Biotechnologies, have done to fast-track their developmental pipeline.
Presenter:
- Max M Søgaard, PhD, Vice President at ExpreS2ion Biotechnologies ApS.
- Ali Salanti, PhD, Professor of Translational Microbiology; Co-Founder & Board Member at AdaptVac ApS
- Louise Leth Hefting, PhD, Field Application Scientist at ChemoMetec A/S
- Janny Marie L Peterslund, PhD, Scientific Affairs Manager at ChemoMetec A/S
Join us for this Science Talk with Drs. Ali Salanti, Max M Søgaard, and Louise Leth Hefting on development of a virus-like particle (VLP)-based COVID-19 vaccine and what the companies behind it, AdaptVac and ExpreS2ion Biotechnologies, have done to fast-track their developmental pipeline.
In this science talk you’ll learn:
- Learn about the capsid VLP and ExpreS2™ technologies
- Get the insights on fast-tracking a COVID-19 vaccine
- What did AdaptVac and EspreS2ion learn through this developmental work?
- How did they work with industry partner ChemoMetec?
- What are Salanti and Søgaard’s take on the COVID-19 vaccine landscape?
Duration: 36 minutes